Clinical trials
Lymphoma clinical trials
Cancer of the lymphatic system, part of the body’s immune defenses. We’re tracking 1,332 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06620835RecruitingPhase 2
Optimizing local treatments for ALK-positive lung cancer on brigatinib
This trial is for people with advanced ALK-positive lung cancer who are already taking the targeted therapy brigatinib and have a few remaining spots of cancer. It tests whether adding local treatments (like surgery, focused radiation, or ablation) to the remaining spots can improve outcomes.
BrestAges 18 years+ - NCT06583395Enrolling by invitation
Meditation retreat study with fitness tracker
This trial studies people attending a 7-day meditation retreat to see how meditation affects well-being. You will wear a fitness tracker and answer surveys.
Palm Desert, CaliforniaAges 21 years+ - NCT06563245RecruitingPhase 2/Phase 3
Brentuximab vedotin for Hodgkin lymphoma in children and young adults
This trial tests the drug brentuximab vedotin for children and young adults (ages 2 to under 35) who have just been diagnosed with classical Hodgkin lymphoma. The treatment is guided by PET/CT scans to see how well it works.
ShanghaiAges 2–35 - NCT06560879Enrolling by invitationPhase 2
Probiotics to prevent stomach problems in children with leukemia
This trial tests whether probiotics can help prevent stomach and gut side effects from chemotherapy in children with leukemia. If your child is between 6 and 17, in the right phase of treatment, and doesn't have any major gut issues, they may be eligible.
Mexico City, CoyoacanAges 6–17 - NCT06565689RecruitingPhase 1
YK012 for B-cell non-Hodgkin lymphoma after prior treatments
This study tests a new daily pill called YK012 for people with certain types of B-cell non-Hodgkin lymphoma that have not responded to at least two prior treatments. The goal is to see if it is safe and if it can shrink tumors.
Beijing, Beijing MunicipalityAges 18–65 - NCT06553872RecruitingPhase 2
Pirtobrutinib and CAR T-cell therapy for mantle cell lymphoma
This trial tests if adding the targeted therapy pirtobrutinib before CAR T-cell treatment (Tecartus) works better for mantle cell lymphoma that has come back or not responded to other treatments. It aims to improve outcomes for patients who are eligible for CAR T-cell therapy.
Stanford, CaliforniaAges 18 years+ - NCT06350994Recruiting
Early Heart Check After CAR-T Cell Treatment
This study checks your heart function early after CAR-T cell cancer treatment. It uses a quick heart ultrasound to look for changes soon after the infusion.
ParisAges 18 years+ - NCT06539182RecruitingPhase 2
DZD8586 for relapsed or refractory CLL/SLL
This trial tests a new oral drug called DZD8586 for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or not responded to previous treatment. The goal is to see if it can help control the disease.
Hefei, AnhuiAges 18 years+ - NCT06534918Recruiting
Nutrition and exercise coaching for cancer survivors
This study tests whether personalized nutrition and exercise coaching helps cancer survivors improve their health after treatment. If you have had breast, prostate, colorectal, or lymphoma cancer and finished your main treatment at least 6 months ago, you may qualify.
Miami, FloridaAges 18 years+ - NCT06517511RecruitingPhase 2
Selinexor plus R-CHOP for first-line treatment of TP53-mutated DLBCL
This trial tests adding selinexor to the standard R-CHOP chemotherapy for people with a specific type of diffuse large B-cell lymphoma (DLBCL) that has a TP53 mutation. The goal is to see if this combination works better as the first treatment.
Guangzhou, GuangdongAges 18–80 - NCT06522932RecruitingPhase 1
PET imaging study for people getting CAR-T therapy for lymphoma
This trial tests a special PET imaging agent (64Cu-GRIP B) to see if it can help track how well CAR-T therapy is working in people with non-Hodgkin lymphoma. It is for patients who have had at least one prior treatment and are scheduled to receive a standard CD19-targeting CAR-T product.
San Francisco, CaliforniaAges 18 years+ - NCT06495723RecruitingPhase 1/Phase 2
Antibody therapy for relapsed T-cell lymphoma
This trial tests a new experimental antibody therapy for people with certain types of peripheral T-cell lymphoma that have not responded to or have come back after prior treatment. The study aims to see if the treatment is safe and effective.
CaenAges 18 years+ - NCT06500273RecruitingPhase 2
Cema-cel for high-risk lymphoma after first treatment
This trial tests a new treatment called cema-cel for people with large B-cell lymphoma who are in remission after first-line therapy but still have tiny amounts of cancer detected by a sensitive blood test. The goal is to prevent the cancer from coming back.
Gilbert, ArizonaAges 18 years+ - NCT06484985RecruitingPhase 1
Testing AXT-1003 for advanced blood cancers and solid tumors
This trial tests a new drug (AXT-1003) for people with advanced blood cancers (like non-Hodgkin lymphoma) or solid tumors that have not responded to standard treatments. The goal is to see if the drug is safe and how well it works.
BeijingAges 18 years+ - NCT06487624RecruitingPhase 1
Study of HCB301 for advanced solid tumors and Hodgkin lymphoma
This trial tests a new drug called HCB301, which targets proteins that help cancer hide from the immune system. It is for people with advanced solid tumors or classical Hodgkin lymphoma who have tried other treatments without success.
Greenville, South CarolinaAges 18 years+ - NCT05107674RecruitingPhase 1
Early drug study for advanced cancers that have limited options
This Phase 1 study tests NX-1607 in adults with advanced cancers that are hard to treat with standard care. It focuses on safety and early signs of how well the drug may work in specific cancer types.
Duarte, CaliforniaAges 18 years+ - NCT06486337RecruitingPhase 2
CMOP±R for untreated non-Hodgkin's lymphoma
This trial tests a combination of chemotherapy drugs (CMOP with or without R) for people with newly diagnosed non-Hodgkin's lymphoma who have not received treatment yet. It aims to see how well the treatment works and if it is safe.
Suzhou, JiangsuAges 18–75 - NCT06487247Recruiting
Home transfusion program for blood cancer patients
This trial offers red blood cell or platelet transfusions at home for people with blood cancer who are no longer responding to treatment. It aims to improve comfort and quality of life by avoiding hospital visits.
Boston, MassachusettsAges 18 years+ - NCT06481826Recruiting
Glofitamab for Chinese patients with relapsed or refractory DLBCL
This trial tests a drug called glofitamab for people with a type of lymphoma (DLBCL) that has come back or not responded to at least two prior treatments. The goal is to see if this drug can help shrink tumors or stop the disease from progressing.
Beijing, Beijing MunicipalityAges 18–80 - NCT06471296Recruiting
How viruses affect tumors and treatment response
This study looks at tumor samples from people with certain cancers to compare those caused by viruses (like HPV, HIV, or EBV) with those not caused by viruses. The goal is to understand why some tumors respond differently to treatments, which may help improve future treatment approaches.
ParisAges 18–100 - NCT06466122RecruitingPhase 2
Pirtobrutinib plus Venetoclax for resistant CLL or SLL
This trial tests two oral targeted drugs—pirtobrutinib and venetoclax—for people with CLL or SLL whose disease has continued to grow despite taking a BTK inhibitor (such as ibrutinib, acalabrutinib, or zanubrutinib). The goal is to see if this combination can control the cancer when a BTK inhibitor alone is no longer working.
Columbus, OhioAges 18 years+ - NCT06451497RecruitingPhase 1
Testing ZM008 alone and with toripalimab for advanced cancers
This trial tests a new drug called ZM008, which targets a protein on some cancer cells, first alone and then combined with another drug, toripalimab, for people with advanced solid tumors that have stopped responding to standard treatments.
Boston, MassachusettsAges 18 years+ - NCT06441331RecruitingPhase 1
Lu-177 edotreotide for children with SSTR-positive tumors
This trial tests a radioactive drug called Lu-177 edotreotide for children with a certain type of tumor (SSTR-positive) that hasn't responded to other treatments. The goal is to find the right dose and see how safe it is.
San Francisco, CaliforniaAges 2–18 - NCT06447376RecruitingPhase 1
Testing siltuximab before epcoritamab to prevent cytokine release syndrome
This trial tests whether giving siltuximab before epcoritamab can help prevent or reduce cytokine release syndrome (a possible side effect where the immune system overreacts). It is for people with certain types of non-Hodgkin lymphoma that have not responded well to at least two prior treatments.
Cleveland, OhioAges 18–65
Hear when a new Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lymphoma?
- Yes. Clin2 currently lists 1,332 recruiting lymphoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lymphoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lymphoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.